|
Generic:
|
|
Daclatasvir
|
|
|
Therapeutic Class:
|
|
Hepatitis C Antivirals
|
|
|
Composition:
|
|
MyDekla 60mg = Each film-coated tablet contains daclatasvir dihydrochloride equivalent to 60mg daclatasvir
|
|
|
Description:
|
|
MyDekla use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults
|
|
Indications
- Hepatitis C genotype 1
- Recurrent HCV infection post-liver transplant
- Hepatitis C genotype 3
|
|
|
Dosage:
|
|
Genotype 1:
- Without cirrhosis: MyDekla plus MyHep for 12 weeks
- Compensated (Child-Pugh A) cirrhosis: MyDekla plus MyHep (sofosbuvir) for 12 weeks
- Decompensated (Child-Pugh B or C) cirrhosis: MyDekla plus MyHep (sofosbuvir) plus ribavirin for 12 weeks
- Posttransplant: MyDekla plus sofosbuvir MyHep (sofosbuvir) plus ribavirin for 12 weeks
Genotype 3:
- Without cirrhosis: MyDekla plus MyHep (sofosbuvir) for 12 weeks
- Compensated (Child-Pugh A) or decompensated (Child-Pugh B or C) cirrhosis: MyDekla plusMyHep (sofosbuvir) plus ribavirin for 12 weeks
- Post transplant: MyDekla plus MyHep (sofosbuvir) plus ribavirin for 12 weeks
|
|
|
Presentation:
|
|
MyDekla 60 mg tab is available in pack of 28 tablets
|
|
|
